Quidel secures CE Mark for Savanna molecular analyzer, assay

By LabPulse.com staff writers

July 12, 2021 -- Quidel has secured the CE Mark for its Savanna molecular analyzer and its Savanna Respiratory Viral Panel-4 (RVP4) Assay, which will allow the firm to market the system in Europe.

Savanna allows users to analyze 12 pathogens in a single test that lasts less than 30 minutes, according to Quidel. Its Savanna RVP4 Assay is a nucleic acid test to detect influenza, respiratory syncytial virus, and SARS-CoV-2, the company said.

Quidel recalls Lyra SARS-CoV-2 assay due to false-negative tests
Quidel is recalling its Lyra SARS-CoV-2 real-time reverse transcription polymerase chain reaction assay for detecting infection with SARS-CoV-2 due to...
Quidel secures EUA for rapid antigen test
Quidel has garnered an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its Sofia Q rapid antigen test, the latest addition...
Quidel secures Health Canada approval for Sofia SARS-CoV-2 test
Health Canada has approved Quidel's Sofia antigen test for the detection of coronavirus infection in both symptomatic and asymptomatic people.
Boom in COVID testing drives Quidel's Q1 financials
Quidel on April 22 announced preliminary numbers for the first quarter of 2021 that saw revenue from the company's line of COVID-19 tests boom to $280 million...
Quidel nabs EUA from FDA for SARS-CoV-2 antigen test
Quidel has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its QuickVue point-of-care assay that detects...

Copyright © 2021 LabPulse.com

Last Updated ls 7/12/2021 3:40:30 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current